IMA-202

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameIMA-202

Drug Alias NameIMA-202

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesImmatics Biotechnologies Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesImmatics Us Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A